Evista (Raloxifene ) & Xigris (Drotrecogin alfa): U.S. Appeals Court Issued ruling in favor of innovator Lilly

The US Court of Appeals for the Federal Circuit (CAFC) in Washington, D.C. overturned a lower court decision and ruled in favor of innovator Eli Lilly (as reported by Lilly in press release Here) in the case between Ariad Pharma v. Eli Lilly.

An earlier jury decision in the U.S. District Court of Massachusetts, and a subsequent bench trial ruling, had deemed that a patent owned by Harvard University, the Massachusetts Institute of Technology and the Whitehead Institute, and licensed to Ariad, was valid and infringed by Lilly's sales of Evista(R) and Xigris(R). Today's ruling by the Court of Appeals overturned that prior decision, concluding that Ariad's patent claims are invalid for failing to meet the written description requirement.

US Court CAFC opinion Here

Earlier news of IP Pharma Doc on this product Here and Here